Isotonische Kochsalzlösung Fresenius clinical trials
3 indexed studies · 0 currently recruiting
- Ongoing, recruitingTherapeutic exploratory (Phase II)
Epirubicin for the Treatment of Sepsis & Septic Shock
This study is testing a medicine called Epirubicin for people in hospital with a serious infection called sepsis. Doctors want to see if it's safe and helps improve their condition. It's an early-stage study to learn more about the medicine's effects.
For: Patients with sepsis or septic shock · currently hospitalized at the Intensive Care Unit (ICU) or Intermediate Care (IMC) regardless where the sepsis was first diagnosed.Germany - Ongoing, recruitingPhase I and Phase II (Integrated)- First administration to humans
A Phase 1/2, adaptive, open-label, single ascending dose to multiple ascending dose study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of mRNA-3745 in participants with glycogen storage disease type 1a (GSD1a), followed by an open-label extension
This study is testing a new medicine, mRNA-3745, for Glycogen Storage Disease Type 1a (GSD1a). It's looking at how safe it is, how well people tolerate it, and how it works in the body, starting with low doses and gradually increasing them.
For: Glycogen storage disease type 1a (GSD1a)Spain · Poland · Netherlands - Ongoing, recruitingTherapeutic confirmatory (Phase III)
A Parallel-Group Treatment, Double-Blind, 2-Arm Study to Investigate the Comparative Efficacy, Safety, and Immunogenicity Between Intravenous AVT16 and Entyvio® in Male and Female Subjects Aged 18 to 80 Years Inclusive with Moderate to Severe Active Ulcerative Colitis
This study is comparing two medicines, AVT16 and Entyvio, for people aged 18-80 with moderate to severe ulcerative colitis. It will check how well they work, how safe they are, and how the body reacts to them over 52 weeks. The main goal is to see if symptoms improve after 6 weeks.
For: Moderate to Severe Active Ulcerative ColitisCroatia · Latvia · Slovakia